Pharmaceuticals and Healthcare

Regeneron agrees to $270m extension to supply Ebola medicine in US

Regeneron Pharmaceuticals has agreed to a nearly $270m contract extension to supply its Ebola therapy, Inmazeb, to the US Government through 2031.

Boehringer and Microsoft collaborate to explore AI in clinical research

Boehringer Ingelheim and Microsoft have entered a strategic collaboration to examine the use of AI in clinical research, beginning with studies in lung health.

Celltrion and Kaigene sign $580m licence deal for KG013

South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene’s investigational monoclonal antibody, KG013, in a deal worth up to Won769bn ($580m).

FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease

The US Food and Drug Administration (FDA) has granted approval for Cosette Pharmaceuticals’ Evoxac oral solution to treat dry mouth symptoms in adults diagnosed with Sjögren’s disease.

Estuary secures $103m to advance kidney disease gene therapies

US-based genetic medicines developer Estuary Biotherapeutics has launched after securing $103m in total committed financing for developing targeted gene therapies to treat kidney diseases.

Gilead Sciences signs five-year DevOps agreement with Cognizant

Gilead Sciences has signed a five-year agreement extension with Cognizant to advance its DevOps environment and support the deployment of agentic AI tools across designated technology initiatives.

Pacira partners with Molteni for Exparel commercialisation

Pacira BioSciences has entered into an exclusive agreement with Italian pharmaceutical company Molteni Farmaceutici to distribute and commercialise Exparel across the EU and the UK.

Bayer plans $2.2bn pharmaceutical manufacturing facility in Ohio, US

Bayer has announced plans to invest $2.2bn in a new pharmaceutical manufacturing facility in Ohio, US.

OBIO marks $704m funding milestone for Canadian health tech ventures

Life sciences and technology companies supported by the Ontario Bioscience Innovation Organization’s (OBIO) Capital Access Advisory Program (CAAP) have collectively raised more than C$1bn ($704.7m) in capital.